Arvinas Past Earnings Performance

Past criteria checks 0/6

ArvinasDie Erträge des Sektors -16.5% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Pharmaceuticals growing auf 8.5% pro Jahr stiegen. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 46.4% pro Jahr gesunken.

Key information

-22.3%

Earnings growth rate

16.7%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	41.3%
Return on equity	-55.7%
Net Margin	-467.9%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Feb 07

Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer

Nov 19

Revenue & Expenses Breakdown
Beta

How Arvinas makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ARVN Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	79	-367	100	380
30 Sep 23	159	-295	88	383
30 Jun 23	158	-298	86	374
31 Mar 23	137	-301	84	346
31 Dec 22	131	-282	80	315
30 Sep 22	127	-253	83	279
30 Jun 22	103	-233	79	242
31 Mar 22	75	-213	70	210
31 Dec 21	54	-191	62	180
30 Sep 21	23	-180	55	152
30 Jun 21	21	-164	48	141
31 Mar 21	21	-139	43	122
31 Dec 20	26	-119	38	108
30 Sep 20	24	-99	33	96
30 Jun 20	47	-86	32	82
31 Mar 20	45	-78	30	75
31 Dec 19	43	-70	27	67
30 Sep 19	42	-65	26	61
30 Jun 19	15	-173	22	58
31 Mar 19	14	-179	17	52
31 Dec 18	14	-240	13	45
30 Sep 18	13	-233	8	37
30 Jun 18	12	-114	5	31
31 Mar 18	10	-98	4	29
31 Dec 17	8	-29	4	29
31 Dec 16	7	-12	3	20

Qualität der Erträge: ARVN ist derzeit unrentabel.

Wachsende Gewinnspanne: ARVN ist derzeit unrentabel.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Ergebnisentwicklung: ARVN ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 16.5% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von ARVN verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: ARVN ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (-17.3%) erschwert.

Return on Equity

Hohe Eigenkapitalrendite: ARVN hat eine negative Eigenkapitalrendite (-64.61%), da es derzeit unrentabel ist.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Arvinas Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy

Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel

Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program

Price target decreased by 7.5% to US$55.82

New minor risk - Share price stability

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 10.0% to US$60.38

Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Consensus revenue estimates increase by 17%

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

New minor risk - Share price stability

Arvinas, Inc. Announces Changes to its Board of Directors

Arvinas, Inc. Announces Interim Data from Phase 1/2 Dose Escalation and Expansion Trial of ARV-766

Consensus revenue estimates increase by 10%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Consensus EPS estimates fall by 12%

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas Announces Changes to Its Board of Directors

Arvinas, Inc. Announces in Post-Hoc Analysis from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Expects VERITAC-2 Phase 3 Trial Population Achieve Clinical Benefit Rate of 62.5%

Price target decreased to US$83.90

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Arvinas, Inc. Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Arvinas, Inc. Announces Changes to its Board of Directors

Chief Medical Officer exercised options and sold US$69k worth of stock

Arvinas, Inc. Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas, Inc. Appoints John Northcott as Chief Commercial Officer

Arvinas: Still Holding, Just Not Buying More

Consensus EPS estimates fall by 12%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

CFO & Treasurer exercised options and sold US$810k worth of stock

Chief Scientific Officer exercised options to buy US$226k worth of stock.

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Chief Scientific Officer notifies of intention to sell stock

Arvinas, Inc. Announces Completed Phase 1 and Interim Phase 2 ARDENT Data for Bavdegalutamide (ARV-110), A Novel PROTAC® Degrader Targeting the Androgen Receptor

Arvinas, Inc. Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 Ardent Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to Present At 2022 ASCO GU Meeting

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Independent Director exercised options and sold US$793k worth of stock

Chief Medical Officer exercised options and sold US$782k worth of stock

CFO & Treasurer notifies of intention to sell stock

Independent Director recently sold US$24m worth of stock

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

Consensus forecasts updated

Consensus forecasts updated

No longer forecast to breakeven

Revenue & Expenses Breakdown
Beta